Titre :

Use of Biologics to Treat Relapsing and/or Refractory Polyarteritis Nodosa: Data from a European Collaborative Study.

Auteur(s) :

Hadjadj, Jerome [Auteur]
Centre de référence des maladies auto-immunes systémiques rares d'Île-de-France / National Reference Center for Rare Systemic Autoimmune Diseases
Canzian, Alice [Auteur]
Karadag, Omer [Auteur]
Contis, Anne [Auteur]
Service de médecine interne et maladies infectieuses [Bordeaux]
Maurier, François [Auteur]
Sanges, Sébastien [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Centre National de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France [CeRAINO]
Sartorelli, Silvia [Auteur]
Denis, Laure [Auteur]
De Moreuil, Claire [Auteur]
Centre Hospitalier Régional Universitaire de Brest [CHRU Brest]
Durel, Cécile-Audrey [Auteur]
Hospices Civils de Lyon [HCL]
Durupt, Stéphane [Auteur]
Hospices Civils de Lyon [HCL]
Jachiet, Marie [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Rouzaud, Diane [Auteur]
AP-HP - Hôpital Bichat - Claude Bernard [Paris]
Salvarani, Carlo [Auteur]
Padoan, Roberto [Auteur]
Dagna, Lorenzo [Auteur]
Bonnet, Fabrice [Auteur]
Centre Hospitalier Universitaire de Bordeaux [CHU Bordeaux]
Agard, Christian [Auteur]
Nantes Université [Nantes Univ]
Moulinet, Thomas [Auteur]
Ingénierie Moléculaire et Physiopathologie Articulaire [IMoPA]
Hermet, Marion [Auteur]
Sterpu, Raluca [Auteur]
AP-HP - Hôpital Antoine Béclère [Clamart]
Maria, Alexandre Thibault Jacques [Auteur]
Centre Hospitalier Régional Universitaire [Montpellier] [CHRU Montpellier]
Keraen, Jeremy [Auteur]
Centre Hospitalier Intercommunal de Cornouaille [CHIC]
Guillevin, Loïc [Auteur]
Service de médecine interne et centre de référence des maladies rares [CHU Cochin]
Jayne, David [Auteur]
Terrier, Benjamin [Auteur]
Service de médecine interne et centre de référence des maladies rares [CHU Cochin]

Titre de la revue :

Rheumatology

Nom court de la revue :

Rheumatology (Oxford)

Numéro :

62

Pagination :

341–346

Date de publication :

2022-06-11

ISSN :

1462-0332

Mot(s)-clé(s) en anglais :

Polyarteritis nodosa
biologics
tocilizumab
rituximab
TNF-alpha
blocker

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Objectives To describe the effectiveness and safety of biologics for the treatment of relapsing and/or refractory polyarteritis nodosa (PAN). Methods A retrospective European collaborative study was conducted in ...
Lire la suite >Objectives To describe the effectiveness and safety of biologics for the treatment of relapsing and/or refractory polyarteritis nodosa (PAN). Methods A retrospective European collaborative study was conducted in patients with PAN who received biologics for relapsing and/or refractory disease. Results Forty-two patients with PAN received a total of 53 biologic courses, including TNF-α blockers in 15 cases, rituximab (RTX) in 18 cases, tocilizumab (TCZ) in 10 cases and other biologics in 10 cases. TNF-α blockers and TCZ were mainly used for refractory diseases whereas RTX was mainly initiated for relapsing disease. After a median follow-up of 29 (8–50) months, remission, partial response, treatment failure and treatment discontinuation due to severe adverse events occurred in, respectively, 40%, 13%, 40% and 7% of patients receiving TNF-α blockers, 50%, none, 30% and 20% of TCZ recipients, and 33%, 11%, 56% and none of the RTX recipients. No remission was noted in patients treated with other biologics. Severe adverse events were observed in 14 (28%) patients without significant differences between the three biologics, leading to early biologics discontinuation in only three cases. Conclusion These results suggest that TCZ may be effective in relapsing and/or refractory PAN. Our data warrant further study to confirm these findings.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Date de dépôt :

2024-01-12T01:17:43Z
2024-03-13T09:31:59Z